Tools

LEADER 02595cam 2200493 i 4500

001 ocn852784168;

003 OCoLC;

005 20180316110332.0;

006 m o d f ;

007 cr bn||||a||||;

008 130713s2002 dcu ob f000 0 eng c;

019 a| 654299303a| 777353954a| 1028572795a| 1028649918;

035 a| (Sirsi) o852784168;

042 a| pcc;

043 a| n-us---;

049 a| ERE#;

074 a| 1019-C-01 (online);

086 0 a| Y 4.C 73/8:107-140;

245 10 a| Examining issues related to competition in the pharmaceutical marketplace :b| a review of the FTC report, generic drug entry prior to patent expiration : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, June 13 and October 10, 2002.;

246 30 a| Generic drug entry prior to patent expiration;

264 1 a| Washington, DC :b| U.S.Government Printing Office,c| 2002.;

300 a| 1 online resource (iii, 142 pages);

336 a| textb| txt2| rdacontent;

337 a| computerb| c2| rdamedia;

338 a| online resourceb| cr2| rdacarrier;

500 a| "Serial No. 107-140.";

500 a| CRDP Program record.;

504 a| Includes bibliographical references.;

588 a| Description based on online resource, PDF version; title from title page (FDsys, viewed Feb. 8, 2018).;

650 0 a| Generic drugs.=| ^A434409;

650 0 a| Drugsx| Pricesz| United States.=| ^A30023;

650 0 a| Competition.=| ^A31720;

650 0 a| Pharmaceutical industry.=| ^A3655;

655 7 a| Legislative hearings.2| lcgft;

700 1 a| Muris, Timothy J.=| ^A318180;

776 08 i| Microfiche version:a| United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health.t| Examining issues related to competition in the pharmaceutical marketplacew| (OCoLC)51932126;

856 40 u| https://purl.fdlp.gov/GPO/gpo89001;

949 a| Click on web addressw| asish| joyner94;

596 a| 1;

998 a| 4825085;

999 a| CLICK ON WEB ADDRESSw| ASISc| 1i| 4825085-1001l| JNETm| JOYNERr| Ys| Yt| JNE1DOu| 3/12/2018x| EDOCUMENTz| JERESOURCE;

Examining issues related to competition in the pharmaceutical marketplace : a review of the FTC report, generic drug entry prior to patent expiration : hearing before the Subcommittee on Oversight and Investigations of the Committee on Energy and Commerce, House of Representatives, One Hundred Seventh Congress, second session, June 13 and October 10, 2002.

Author/creator	United States
Other author	Muris, Timothy J.
Format	Electronic
Publication	Washington, DC : U.S.Government Printing Office, 2002.
Description	1 online resource (iii, 142 pages)
Supplemental Content	https://purl.fdlp.gov/GPO/gpo89001
Subjects	Generic drugs. Drugs--Prices. --United States. Competition. Pharmaceutical industry.

Portion of title	Generic drug entry prior to patent expiration
General note	"Serial No. 107-140."
General note	CRDP Program record.
Bibliography note	Includes bibliographical references.
Source of description	Description based on online resource, PDF version; title from title page (FDsys, viewed Feb. 8, 2018).
Issued in other form	Print version: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Examining issues related to competition in the pharmaceutical marketplace
Issued in other form	Microfiche version: United States. Congress. House. Committee on Energy and Commerce. Subcommittee on Health. Examining issues related to competition in the pharmaceutical marketplace
Genre/form	Legislative hearings.
GPO item number	1019-C-01 (online)
Govt. docs number	Y 4.C 73/8:107-140

Click here for more information about this title